Search

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

Saul Ewing securities attorneys Justin B. Ettelson, Michael A. Gold, Mark I. Gruhin, Andrew F. Barris and Jourdan S. Garvey have co-edited the 2021 edition of SEC Reporting Rules books.* For those responsible for filing reports with the SEC for public companies, the 2021 SEC Reporting Rules books...